



Tuesday, 15 May 2018

Break
08:00 - 09:30

Foyer

Registration and Welcome Coffee

Plenary Session
09:30 - 10:00

Congress Hall

Welcome Address

CIMT President Christoph Huber

09:30 - 10:00

Plenary Session
10:00 - 11:30

Congress Hall

Cellular Therapy

Chair: Michael Kalos (The Janssen Pharmaceutical Companies, Spring House, United States)
Chair: Harpreet Singh (Immatics Biotechnologies, Houston, United States)

New modes of T-cell cancer recognition by dissection of immunotherapy successes

10:00 - 10:30

Speaker: Andrew Sewell (Cardiff University, Cardiff, United Kingdom)

ADAPting to solid tumors, advances and challenges for TCR T-cell therapy

10:30 - 11:00

Speaker: Gwen Binder-Scholl (Adaptimmune, Philadelphia, United States)

TIL therapy in melanoma: history of clinical development, current status and plans for the future

11:00 - 11:30

Speaker: Rodabe Amaria (University of Texas MD Anderson Cancer Center, Houston, United States)

Break
11:30 - 13:30

Foyer

Lunch

Corporate Supported Symposium
12:00 - 13:00

Congress Hall

"Immunooncology 2018 and beyond" supported by Bristol-Myers Squibb

Chair: Dirk Jäger (National Center for Tumor Diseases, Heidelberg, Germany)

Immunooncology from mono- to combination therapy - a clinical perspective	12:00 - 12:20
Speaker: Viktor Grünwald (Medical School Hannover (MHH), Hanover, Germany)	
Resistance to immunotherapy	12:20 - 12:40
Speaker: Guy Ungerechts (National Center for Tumor Diseases, Heidelberg, Germany)	
Biomarkers in immunooncology - can we predict the outcome of therapy?	12:40 - 13:00
Speaker: Andreas Jung (Ludwig-Maximilians-Universität, Munich, Germany)	

Plenary Session
13:30 - 15:00

Congress Hall

Counteracting Immune Escape

Chair: Cornelis Melief (ISA Pharmaceuticals, Leiden, Netherlands)
Chair: Thorbald van Hall (Leiden University Medical Center, Leiden, Netherlands)

TNFR family members and cancer immunotherapy: lessons from chronic infection	13:30 - 14:00
Speaker: Tania Watts (University of Toronto, Toronto, Canada)	
title of talk to be announced	14:00 - 14:30
Speaker: Melody Swartz (University of Chicago, Chicago, United States)	
Regulation of dendritic cells in tumors	14:30 - 15:00
Speaker: Jan P. Böttcher (Technical University Munich, Munich, Germany)	

Break
15:00 - 16:00

Foyer

Coffee Break

Poster Session
15:00 - 18:00

East and West Foyers

Poster Exhibit I

Plenary Session
18:00 - 19:00

Congress Hall

Keynote Lecture

Chair: Christoph Huber (CIMT, Mainz, Germany)

Highly multiplex 2D and 3D imaging of the immune system and tumors	18:00 - 19:00
Speaker: Ronald Germain (NIAD, NIH, Bethesda, United States)	

Plenary Session
08:00 - 09:30

Congress Hall

Tumor Microenvironment

Chair: Viktor Umansky (German Cancer Research Center DKFZ, Heidelberg, Germany)
Chair: Günter Hämmerling (German Cancer Research Center DKFZ, Heidelberg, Germany)

Potent and durable tumor immunity induced by ADU-S100, a first-in-class STING agonist **08:00 - 08:30**

Speaker: Andrea van Elsas (Aduro Biotech, Oss, Netherlands)

The Ying and Yang of TAM: Macrophages as effector cells for cytotoxic antibodies in vivo **08:30 - 09:00**

Speaker: Falk Nimmerjahn (Friedrich-Alexander-University, Erlangen, Germany)

Myelopoiesis and cancer: "Flipping" over monocytes into immune suppressive cells **09:00 - 09:30**

Speaker: Vincenzo Bronte (University of Verona, Verona, Italy)

Break
09:30 - 10:00

Foyer

Coffee Break

Short Talk Session
10:00 - 11:30

Congress Hall

Short Talk Session I Tumor Biology and Interaction with the Immune System

Chair: Hansjörg Schild (Institute for Immunology at the University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany)
Chair: Steve Pascolo (University Hospital Zurich, Zurich, Switzerland)

Monitoring of T cell infiltration and positioning in colorectal cancer liver metastases using a human tissue-based ex vivo cell migration analysis model **10:00 - 10:15**

Speaker: Anna Berthel (German Cancer Research Center and National Center for Tumor Diseases, Heidelberg, Germany)

The oncometabolite R-2-hydroxyglutarate suppresses T cell immunity in IDH1-mutant gliomas **10:15 - 10:30**

Speaker: Theresa Bunse (German Cancer Research Center, Heidelberg, Germany)

Single-cell transcriptome analysis unveils a heterogeneous and dynamic landscape of tumor infiltrating CD8 T cells **10:30 - 10:45**

Speaker: David Gfeller (University of Lausanne, Epalinges, Switzerland)

In vivo siRNA knockdown of Wnt1 rescues dendritic cells from b-catenin activation and sensitizes tumors to vaccination **10:45 - 11:00**

Speaker: Dimitra Kerdidani (BSRC Fleming, Vari, Greece)

RIG-I-like helicases signaling induced alteration of myeloid-derived suppressor cells phenotype and function unleashes tumor immune control in murine pancreatic cancer **11:00 - 11:15**

Speaker: Sabrina Viktoria Kirchleitner (Ludwig-Maximilians-Universität München, Munich, Germany)

Tumor microenvironment T-cell repertoire and mutational load are independently associated with the outcome of sequential checkpoint inhibition in melanoma **11:15 - 11:30**
Speaker: Erik Yusko (Adaptive Biotechnologies, Seattle, United States)

Short Talk Session
10:00 - 11:30

Gutenberg Hall A

Short Talk Session II Cellular Therapy

Chair: Sébastien Wälchli (Oslo University Hospital, Oslo, Norway)
Chair: Isabel Poschke (German Cancer Research Center DKFZ, Heidelberg, Germany)

The recognition patterns of T cell receptors identified using peptide-MHC multimers labeled with DNA barcodes **10:00 - 10:15**
Speaker: Amalie Kai Bentzen (Technical University of Denmark, Lyngby, Denmark)

In vivo generation of CD4+ and CD8+ CAR-T cells by receptor-targeted lentiviral vectors **10:15 - 10:30**
Speaker: Julia D. S. Hanauer (Paul-Ehrlich-Institut, Langen, Germany)

Neoantigen-specific CD8 T cells are structurally and functionally overlapping with CD8 T cells recognizing shared self-tumor and viral epitopes **10:30 - 10:45**
Speaker: Morgane Magnin (Lausanne University Hospital Centre (CHUV), Epalinges, Switzerland)

Super-resolution microscopy dSTORM reveals CD19dim expression on a subset of myeloma cells that can be targeted with CD19-CAR T cells **10:45 - 11:00**
Speaker: Thomas Nerreter (Universitätsklinikum Würzburg, Würzburg, Germany)

Off-target toxicity risk evaluation for TCR-based therapies guided by immunopeptidomics data of a comprehensive set of more than 650 primary normal tissue samples **11:00 - 11:15**
Speaker: Heiko Schuster (Immatix Biotechnologies GmbH, Tübingen, Germany)

Intestinal graft-versus-host disease is driven by BATF-dependent IL-7RhiGM-CSF+ T cells **11:15 - 11:30**
Speaker: Evelyn Ullrich (Johann Wolfgang Goethe-University, Children's Hospital, Frankfurt, Germany)

Short Talk Session
10:00 - 11:30

Gutenberg Hall B

Short Talk Session III New Targets & New Leads

Chair: John Castle (Agenus Inc, Lexington, United States)
Chair: Angelika Riemer (German Cancer Research Center DKFZ, Heidelberg, Germany)

Identification of a naturally presented myeloma-associated BCMA peptide as an immunogenic T-cell epitope for immunotherapeutic approaches **10:00 - 10:15**
Speaker: Tatjana Bilich (University of Tübingen, Institute for Cell Biology, Tübingen, Germany)

Immunopeptidomic profiling of triple negative breast cancer identifies potential immunotherapy target antigens **10:15 - 10:30**
Speaker: Demin Li (University of Oxford, Oxford, United Kingdom)

KY1055: a novel ICOS/PD-L1 bispecific antibody, enhances T cell activation and delivers potent monotherapy anti-tumour responses in vivo **10:30 - 10:45**
Speaker: Matthew McCourt (Kymab, Cambridge, United Kingdom)

Glyco-engineering of an anti-CD40 antibody enhances its agonistic activity	10:45 - 11:00
Speaker: Phillip Schiele (GlycoTope GmbH, Berlin, Germany)	
Database matching of de novo sequencing candidates - a new strategy for MHC peptide identification	11:00 - 11:15
Speaker: Andreas Schlosser (Universität Würzburg, Würzburg, Germany)	
Theranostic tumor imaging of neuroblastoma using radiolabeled αCD276-antibody	11:15 - 11:30
Speaker: Dominik Sonanini (Eberhard Karls University of Tübingen, Tübingen, Germany)	

Break
11:30 - 14:00

Foyer

Lunch

Plenary Session
12:00 - 13:30

Congress Hall

CAR T-Cell Therapy organized by CARAT

Chair: Christian Buchholz (Paul-Ehrlich-Institut, Langen, Germany)
Chair: Andrew Kaiser (Miltenyi Biotech, Bergisch Gladbach, Germany)

Chimeric antigen receptor T cells: advances in cellular engineering and clinical development	12:00 - 12:30
Speaker: Bruce Levine (University of Pennsylvania, Philadelphia, United States)	
T-cell engineering for cancer applications	12:30 - 13:00
Speaker: Martin Pule (University College London, London, United Kingdom)	
Cell therapy between academic research and company driven drug development	13:00 - 13:30
Speaker: Peter Borchmann (University Hospital of Cologne, Cologne, Germany)	

Plenary Session
14:00 - 15:30

Congress Hall

Combination Therapies

Chair: Sjoerd H. van der Burg (Leiden University Medical Center, Leiden, Netherlands)
Chair: Dirk Jäger (National Center for Tumor Diseases, Heidelberg, Germany)

Stromal activation in cancer immunology and immunotherapy	14:00 - 14:30
Speaker: Shannon Turley (Genentech, San Francisco, United States)	
Mechanistic insights into the immune adjuvant effect of radiotherapy	14:30 - 15:00
Speaker: Sandra Demaria (Weill Cornell Medical College, New York, United States)	
The anti-TGFβ neutralizing antibody, SAR439459, blocks immunosuppression and exhibits anti-tumor activity in combination with anti-PD1	15:00 - 15:30
Speaker: Jack Pollard (Sanofi Oncology, Cambridge, United States)	

Break
15:30 - 16:30

Foyer

Coffee Break

Poster Session
15:30 - 18:30

East and West Foyers

Poster Exhibit II

Short Talk Session
15:45 - 16:15

Gutenberg Hall A

Meet the Editor

An editors guide to scientific publishing

15:45 - 16:15

Speaker: Priscilla Kelly (Science Magazine, Washington, DC, United States)

CIMT Members Meeting
17:30 - 19:00

Dijon Room

General Members Assembly of the Association for Cancer Immunotherapy CIMT

19:30 - 24:00

Foyer

Social Event & Poster Award Ceremony

Plenary Session
08:30 - 10:00

Congress Hall

Immunoguiding

Chair: Marij J.P. Welters (Leiden University Medical Center, Leiden, Netherlands)
Chair: Sine Reker Hadrup (Technical University of Denmark, Copenhagen, Denmark)

Reprogramming the tumor microenvironment for efficient cancer immunotherapy **08:30 - 09:00**

Speaker: Günter J. Hämmerling (German Cancer Research Center DKFZ, Heidelberg, Germany)

Complement in cancer: untangling an intricate relationship **09:00 - 09:30**

Speaker: Dimitrios Mastellos (National Center for Scientific Research 'Demokritos', Athens, Greece)

Lung cancer evolution and immune escape **09:30 - 10:00**

Speaker: Nicholas McGranahan (Cancer Research UK Lung Cancer Centre of Excellence, London, United Kingdom)

Break
10:00 - 10:30

Foyer

Coffee Break

Plenary Session
10:30 - 12:30

Congress Hall

Regulatory Research organized by CIMT-RRG and CARAT

Chair: Ulrich Kalinke (TWINCORE, Hanover, Germany)
Chair: Christian Buchholz (Paul-Ehrlich-Institut, Langen, Germany)

Chimeric antigen receptor (CAT) modified T cells - EU regulatory considerations **10:30 - 11:10**

Speaker: Martina Schüssler-Lenz (Committee for Advanced Therapies (CAT), European Medicines Agency, London, United Kingdom)

Translation of CAR-based innovations into clinics: how to overcome the regulatory hurdles **11:10 - 11:50**

Speaker: Bernd Schröder (Miltenyi Biotech, Teterow, Germany)

From Karl Landsteiner to CAR-T cells: from processes to products and patients **11:50 - 12:30**

Speaker: Martin Hildebrandt (Technical University Munich, Munich, Germany)

Short Talk Session
10:30 - 11:45

Gutenberg Hall A

Short Talk Session IV Therapeutic Vaccination

Chair: Sebastian Kreiter (TRON, Mainz, Germany)
Chair: Kris Thielemans (Vrije Universiteit Brussel, Brussels, Belgium)

Bifunctional RNA-nanoparticles to enhance dendritic cell activation and enable MRI-based detection of dendritic cell migration to lymph nodes	10:30 - 10:45
Speaker: Adam Grippin (University of Florida Brain Tumor Immunotherapy Program, Gainesville, United States)	
Enrichment of gene modified cellular melanoma vaccines with melanoma stem cells or inducible pluripotent stem cells increases immunogenicity and clinical effectiveness in mice	10:45 - 11:00
Speaker: Andrzej Mackiewicz (Poznań University of Medical Sciences, Poznań, Poland)	
Local radiotherapy and E7-RNA-LPX vaccination activate non-redundant mechanisms and lead to complete tumor rejection of well-established HPV16+ TC-1 tumors	11:00 - 11:15
Speaker: Nadja Salomon (TRON, Mainz, Germany)	
NKG2A blockade potentiates CD8+ T-cell immunity induced by cancer vaccines	11:15 - 11:30
Speaker: Thorbald van Hall (Leiden University Medical Center, Leiden, Netherlands)	
Biomaterial-based scaffolds improve delivery of therapeutic nanoparticle cancer vaccines to dendritic cells	11:30 - 11:45
Speaker: Jorieke Weiden (Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, Netherlands)	

Short Talk Session
10:30 - 11:45

Gutenberg Hall B

Short Talk Session V Immunomonitoring

Chair: Cecile Gouttefangeas (University of Tübingen, Tübingen, Germany)
Chair: Dimitrios Mastellos (National Center for Scientific Research 'Demokritos', Athens, Greece)

High dimensional analysis of the myeloid cell landscape in human breast cancer metastatic lymph nodes	10:30 - 10:45
Speaker: Rodrigo Nalio Ramos (Institute Curie, Paris, France)	
The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival	10:45 - 11:00
Speaker: Saskia J.A.M. Santegoets (Leiden University Medical Center, Leiden, Netherlands)	
Empty MHC class I molecules: An alternate, convenient, and improved detection tool for antigen specific T cells	11:00 - 11:15
Speaker: Tripti Tamhane (Technical University of Denmark, Lyngby, Denmark)	
Immunomonitoring for personalized cancer immunotherapies via ex vivo combinatorial workflow and concurrent high-resolution class I & II ICS	11:15 - 11:30
Speaker: Alexander Ulges (Immatic Biotechnologies GmbH, Tübingen, Germany)	
Disappearance of NY-ESO-1 and Melan-A-specific T-cells from peripheral blood is associated with clinical response in melanoma patients undergoing anti-PD-1 therapy	11:30 - 11:45
Speaker: Henning Zelba (University Medical Center Tübingen, Tübingen, Germany)	

Short Talk Session
11:45 - 13:00

Gutenberg Hall A

Short Talk Session VI Improving Immunity

Chair: Mustafa Diken (TRON, Mainz, Germany)
Chair: Onur Boyman (University Hospital Zurich, Zurich, Switzerland)

Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable treatment of solid tumors with T cell therapies	11:45 - 12:00
Speaker: Riikka Havunen (University of Helsinki, Helsinki, Finland)	
Intratumoral RNA treatment: a promising approach for the therapy of solid tumors	12:00 - 12:15
Speaker: Regina Heidenreich (CureVac AG, Tübingen, Germany)	
Human interleukin-2 (IL-2)/anti-IL-2 antibody complexes preferentially stimulate effector cells and show strong efficacy in tumor models	12:15 - 12:30
Speaker: Andreas Katopodis (Novartis Institutes of Biomedical Research, Basel, Switzerland)	
Activin-A protects against lung cancer progression by potentiating anti-tumor immunity	12:30 - 12:45
Speaker: Ioannis Morianos (Biomedical Research Foundation of the Academy of Athens, Athens, Greece)	
Loss of myeloid cell GCN2 drives progression in experimental melanomas during immune checkpoint inhibition	12:45 - 13:00
Speaker: Jana K. Sonner (German Cancer Research Center DKFZ, Heidelberg, Germany)	

Short Talk Session
11:45 - 13:00

Gutenberg Hall B

Short Talk Session VII Clinical Trials

Chair: Anthony Kong (University of Birmingham, Birmingham, United Kingdom)

Chair: Stephan Grabbe (University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany)

HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients	11:45 - 12:00
Speaker: Luigi Buonaguro (Istituto Nazionale Tumori Pascale, Napoli, Italy)	
CetuGEX and Cetuximab in recurrent/metastatic squamous cell carcinoma of the head and neck (RM-HNSCC) - p16+ subgroup analysis of the phase 2 RESGEX study	12:00 - 12:15
Speaker: Beate Habel (Glycotope GmbH, Berlin, Germany)	
The safety, tolerability, and preliminary clinical activity of the CXCR4 inhibitor X4P-001 and nivolumab in renal cell carcinoma patients that are refractory to nivolumab monotherapy	12:15 - 12:30
Speaker: Lu Gan (X4 Pharmaceuticals, Cambridge, United States)	
High rate of objective anti-tumor response in 9 patients with primary or recurrent glioblastoma after viro-immunotherapy with oncolytic parvovirus H-1 in combination with bevacicumab and PD-1 checkpoint blockade	12:30 - 12:45
Speaker: Karsten Geletneky (Klinikum Darmstadt, Darmstadt, Germany)	
Human IL-10 (AM0010, Pegilodecakin) in combination with immune checkpoint blockade	12:45 - 13:00
Speaker: Martin Oft (ARMO BioSciences, Redwood City, United States)	

Break
13:00 - 14:00

Foyer

Lunch

Therapeutic Vaccination

Chair: Hans-Georg Rammensee (University of Tübingen, Tübingen, Germany)

Chair: Carl Figdor (Radboud University Medical Center, Nijmegen, Netherlands)

Dendritic cell-based vaccination against cancer

14:00 - 14:30

Speaker: Jolanda de Vries (Radboud University Medical Center, Nijmegen, Netherlands)

Personalized RNA vaccines

14:30 - 15:00

Speaker: Özlem Türeci (German Cluster of Individualized Immunointervention (CI3), Mainz, Germany)

Therapeutic cancer vaccine for combination with immune checkpoint blockade therapy: formulation matters

15:00 - 15:30

Speaker: Yared Hailemichael (MD Anderson Cancer Center, Houston, United States)